Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOARGYS vs DEMULEN 1/50-28
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LOARGYS is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Acute gouty arthritis,Dysmenorrhea,Management of acute pain
FDA: Prevention of pregnancy,Off-label: Treatment of acne vulgaris, dysmenorrhea, endometriosis-related pain, menstrual irregularity
100 mg orally twice daily.
One tablet orally once daily for 28 consecutive days per cycle.
Terminal elimination half-life: 12-18 hours (prolonged in renal impairment).
Ethinylestradiol: terminal elimination half-life ~13-27 hours (mean ~17 hours); ethynodiol diacetate (as norethindrone): terminal elimination half-life ~8-11 hours; clinical context: achieved steady-state within 5-10 days; accumulation not significant due to dose interval.
Hepatic metabolism primarily via cytochrome P450 enzymes, including CYP2C9; formation of inactive metabolites, with less than 1% excreted unchanged in urine.
Ethinyl estradiol: CYP3A4; undergoes first-pass metabolism with sulfation and glucuronidation. Ethynodiol diacetate: Deacetylated to norethynodrel, then extensively metabolized via reduction and conjugation.
Primarily renal (70-80% unchanged; 10-15% as metabolites); biliary/fecal (5-10%).
Ethinylestradiol and ethynodiol diacetate are extensively metabolized; urinary excretion accounts for ~40% of ethinylestradiol metabolites and ~50-60% of ethynodiol diacetate metabolites; fecal excretion accounts for ~30% of ethinylestradiol metabolites and ~35% of ethynodiol diacetate metabolites; biliary excretion contributes to enterohepatic circulation.
85-90% (primarily albumin).
Ethinylestradiol: >97% bound, primarily to albumin, with ~2% bound to sex hormone-binding globulin (SHBG); ethynodiol diacetate (as norethindrone): ~95% bound, primarily to albumin and SHBG.
0.5-0.7 L/kg (indicates moderate tissue distribution).
Ethinylestradiol: Vd ~2-4 L/kg; distributes extensively into body tissues; ethynodiol diacetate (as norethindrone): Vd ~4 L/kg; indicates wide distribution including reproductive tissues.
Oral: 60-70% (first-pass metabolism).
Oral: ethinylestradiol bioavailability ~40-60% due to first-pass metabolism; ethynodiol diacetate bioavailability ~60-80% after oral administration.
GFR 30-59 m L/min: 75 mg twice daily; GFR 15-29 m L/min: 50 mg twice daily; GFR <15 m L/min: not recommended.
No dosage adjustment required for renal impairment. Use is not recommended in patients with severe renal impairment due to potential adverse effects.
Child-Pugh A: no adjustment; Child-Pugh B: 75 mg twice daily; Child-Pugh C: not recommended.
Contraindicated in patients with Child-Pugh C cirrhosis. For Child-Pugh A or B, use is generally not recommended; if used, monitor closely for adverse effects.
Not established; safety and efficacy not studied in patients <18 years.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally once daily for 28 days per cycle.
No specific dose adjustment required; monitor renal function and adjust based on GFR.
Not indicated for use in postmenopausal women. No specific dose adjustment recommended for elderly, but consider increased risk of thromboembolic disorders.
Cardiovascular thrombotic events: NSAIDs, including LOARGYS, increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. The risk is higher in patients with cardiovascular disease or risk factors. LOARGYS is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Cigarette smoking increases risk of serious cardiovascular events (e.g., myocardial infarction, stroke, thromboembolism). Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Cardiovascular thrombotic events,Gastrointestinal adverse events (bleeding, ulceration, perforation),Hypertension and exacerbation of hypertension,Renal effects: renal papillary necrosis, interstitial nephritis, and acute renal failure,Hepatic effects: elevations of liver enzymes, severe hepatic reactions,Anaphylactic reactions,Serious skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis,Fluid retention and edema,Masking of inflammation and fever
Thromboembolic disorders (DVT, PE, stroke, MI),Hepatic neoplasia (benign/malignant liver tumors),Increased risk of gallbladder disease,Hypertension,Carbohydrate/lipid metabolic effects,Ocular disturbances (retinal thrombosis, optic neuritis),Depression,Fetal harm if used during pregnancy
Hypersensitivity to LOARGYS or any component of the formulation,History of asthma, urticaria, or allergic-type reaction after taking aspirin or other NSAIDs,Patients with active gastrointestinal bleeding, peptic ulcer disease, or perforation,Advanced renal disease,Treatment of perioperative pain in the setting of CABG surgery,Patients with severe heart failure (NYHA Class IV)
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
Avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if taking with potassium-sparing diuretics or in renal impairment. Grapefruit juice may alter drug metabolism; limit intake.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinical significance is unclear. Maintain consistent intake of vitamin C-rich foods as they may increase estrogen absorption. Avoid St. John's wort, which reduces contraceptive efficacy.
FDA Pregnancy Category X. First trimester: high risk of major congenital malformations (e.g., craniofacial defects, neural tube defects). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal renal impairment.
Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimesters: association with masculinization of female fetus, adrenal suppression, and possible long-term metabolic effects. Estrogen component may increase risk of VACTERL anomalies.
Contraindicated during breastfeeding. Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants.
Contraindicated during breastfeeding. Estrogens reduce milk production and quality. M/P ratio not established; ethinyl estradiol and norgestrel are excreted in breast milk in small amounts, potentially causing adverse effects in the infant.
Avoid use during pregnancy due to teratogenicity; no dose adjustment guidelines exist as drug is contraindicated.
No adjustments; absolute contraindication in pregnancy. Drug should be discontinued immediately upon pregnancy diagnosis. No established safe dose in pregnancy.
LOARGYS is an angiotensin II receptor blocker (ARB) indicated for hypertension. Avoid in pregnancy (Pregnancy Category D). Monitor serum potassium and renal function periodically. May cause dizziness; advise caution with driving. Combination with NSAIDs may reduce antihypertensive effect and increase renal risk.
Demulen 1/50-28 is a monophasic combined oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Due to the 50 mcg estrogen dose, it carries an increased risk of venous thromboembolism compared to lower-dose pills; avoid in patients with migraine with aura, hypertension >160/100 mm Hg, or age >35 who smoke. The 28-day pack includes 21 active pills and 7 placebo pills; breakthrough bleeding is more common with higher estrogen. Caution with hepatic enzyme inducers like rifampin or anticonvulsants may reduce efficacy.
Take exactly as prescribed, usually once daily.,Avoid salt substitutes containing potassium unless approved by doctor.,Do not stop taking without consulting your doctor.,Report symptoms like lightheadedness, fainting, or swelling.,Use effective contraception during treatment; not safe in pregnancy.
Take one pill daily at the same time, preferably with food to reduce nausea.,The first 7 days of the first cycle require a backup contraceptive method if not starting on day 1 of menses.,Missed pill: if one active pill is missed, take it as soon as remembered and continue; if two or more active pills are missed, take the last missed pill, skip the others, use backup for 7 days, and consider emergency contraception.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35.,Report symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or severe headache.,The 7 placebo pills are for withdrawal bleeding; start next pack on time regardless of bleeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOARGYS vs DEMULEN 1/50-28, answered by our medical review team.
LOARGYS is a Combination Oral Contraceptive that works by LOARGYS is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.. DEMULEN 1/50-28 is a Combination Oral Contraceptive that works by Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOARGYS and DEMULEN 1/50-28 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOARGYS is: 100 mg orally twice daily.. The standard adult dose of DEMULEN 1/50-28 is: One tablet orally once daily for 28 consecutive days per cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOARGYS and DEMULEN 1/50-28 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOARGYS is classified as Category C. FDA Pregnancy Category X. First trimester: high risk of major congenital malformations (e.g., craniofacial defects, neural tube defects). Second and third trimesters: risk of fetal. DEMULEN 1/50-28 is classified as Category C. Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.